Introduction {#s1}
============

Diabetes mellitus (DM) is a type of chronic illness that requires careful management with medications to keep blood glucose level in recommended range ([@B1]; [@B41]; [@B2]). The disease could result in micro and macro vascular complications that have serious short and long-term repercussions. Estimation of glycated hemoglobin (Hb~A1c~) is done to monitor the disease and forms the basis of treatment recommendations ([@B35]). Patient adherence to anti diabetic medication therapy results in better control of disease and may help to keep Hb~A1c~ in recommended range ([@B5]). There is a plethora of studies that highlight the importance of adhering to medications in type 2 diabetes mellitus ([@B10]; [@B1]; [@B2]; [@B5]). However, it is imperative to improve patients' disease knowledge to achieve high adherence to therapy ([@B43]).

Patient education with an emphasis on adherence to anti diabetic medications and how it contributes positively to disease, would empower them to become compliant to prescribed therapy and, recognize and self-manage disease symptoms at home. Conversely, low literacy regarding disease is associated with poor treatment outcomes and a higher cost of therapy ([@B10]). Therefore, assessment of disease knowledge might be helpful in uncovering one of the determinants of poor disease outcome. Moreover, its relationship with adherence also provides an estimate of the extent to which knowledge translates into patients' efforts for achieving treatment goals ([@B19]; [@B2]). Medication adherence in diabetic patients may be defined as the extent to which a patient remains committed to taking anti diabetic medications in right dose and frequency ([@B5]). Patients and healthcare providers have a role to play in improving medication adherence ([@B14]). Studies have emphasized that improvement in disease knowledge go hand-in-hand with improved medication adherence ([@B45]).

Figures from International Diabetes Federation (IDF) report that globally there were more the 400 million patients living with diabetes in 2015. The World Health Organization estimates that there will be over 592 million patients with type 2 DM in 2035 ([@B42]). The prevalence of type 2 DM in Saudi Arabia was 18.5% and has increased during the past decade ([@B24]). It remains as one of the main causes of death and disability in the country ([@B22]; [@B37]). Saudi Arabia has the second largest diabetic population in the Gulf region and seventh largest in the world ([@B5]). Evidence indicates that DM is more prevalent in urban areas and in males ([@B10]). The crude death rate is estimated to be 2.25% (95% CI: 2.02--2.5%) and accounts for 4.78% of total years lived with disability (95% CI: 3.86--5.7%) ([@B23]) [@B28].

Previous researches have highlighted a low adherence to medication therapy, poor self-management and an unsatisfactory disease knowledge in Saudi patients with diabetes. However, none of the studies investigated the relationship between disease knowledge and medication adherence ([@B1]; [@B6]; [@B8]).

Methods {#s2}
=======

Objective {#s2_1}
---------

The study examined the association between disease knowledge and medication adherence in patients with type 2 diabetes. The study also analyzed relationship between Hb~A1c~ (%) as a proxy for disease control, with adherence and disease knowledge.

Duration and Venue of Study {#s2_2}
---------------------------

A cross-sectional study was conducted for three months in three community pharmacies located in Khobar city of Saudi Arabia. Community pharmacies from three districts of the city were randomly selected.

Target Population and Eligibility Criteria {#s2_3}
------------------------------------------

All adult male and female out-patients, with or without comorbidities, who had established diagnosis of type 2 diabetes mellitus at least three months before the study, were identified as target population for this study. Patients not fulfilling the above criteria and those with an acute illness, diabetes complication and/or planned surgery were considered ineligible.

Participants' Recruitment {#s2_4}
-------------------------

There were three types of patients who visited pharmacies for their medication needs; patients who obtained medicines through government supply, patients with corporate insurance and, patients who paid out-of-pocket cost. All patients had a medical record number (MRN). This MRN was obtained from patients and entered into the pharmacy software to retrieve electronic prescriptions. In addition to being used to check patients' eligibility, the electronic patient records provided Hb~1Ac~ related data. Following confirmation of diabetes, they were briefed about the study. Those who agreed to participate were handed a written informed consent form. Patients who signed the consent were included in the study.

Sampling Procedure and Sample Size {#s2_5}
----------------------------------

Convenience sampling procedure was employed to obtain information from patients who visited the community pharmacies. Data collection was done at a time of convenience, i.e., on weekends during evening hours. This time was selected based on peak visiting hours. The sample size was calculated based on disease prevalence with help of an online sample size calculator ([@B38]). The prevalence of DM according to IDF Report was 18.5% ([@B24]). This figure was entered in the calculator keeping a two-tailed alpha error rate of 0.05%, confidence level was kept at 95% and precision was set at 5%. The required sample size was 232 patients. A drop-out of 30% was added and final sample size required was 302. Post hoc power was calculated and was reported \>85% ([@B15]; [@B21]; [@B44]).

Research Instrument {#s2_6}
-------------------

The research instruments used for evaluation of patient' disease knowledge and medication adherence were the Arabic versions of the Revised Diabetes Knowledge Questionnaire (DKT) and, the General Medication Adherence Scale (GMAS) respectively ([@B16]; [@B9]; [@B20]; [@B30]; [@B29]; [@B29]; [@B31]). The Arabic version of the Revised Diabetes Knowledge Questionnaire (DKT-2) is a 23-item questionnaire containing multiple choice questions (MCQs) to assess the knowledge of diabetes mellitus. It is a validated tool to measure disease knowledge with good internal consistency. The scale assesses a patient's knowledge regarding the disease, complication, diet, treatment and monitoring, etc. ([@B9]). The General Medication Adherence Scale (GMAS) was recently developed and validated in Saudi patients with chronic diseases. It contains 11 items and each item have 4 options ([@B29]). The scale measures adherence to medications considering patient's behaviors, comorbidities and out-of-pocket expenditures. Each option awards a score and sum of all individual scores yields a patient's adherence to medication ([@B30]; [@B29]; [@B31]).

Data Analyses {#s2_7}
-------------

The data obtained were analyzed through SPSS version 23 and expressed as sample counts (N) and percentages (%). The data were checked for distribution and outliers by informal methods ([@B18]; [@B25]). Based on data distribution, descriptive statistics as mean (X) and standard deviation (SD) were used for normally distributed data while median (M) and interquartile range (IQR) were used to report non-normally distributed data. Percentiles were used to report categorical data. Chi-square (χ^2^) test and cross tabulation was used to examine the association between patient demographics and medication adherence. Spearman's rank correlation (r) was employed to report the relationship between disease knowledge and medication adherence. Adherence was assessed using multivariable logistic regression models, adjusting for patient baseline characteristics by using significant variables obtained from the Chi-Square (χ^2^) tests. The reliabilities of the GMAS and DKT questionnaires were analyzed using Cronbach alpha (α) ([@B17]; [@B15]).

Ethical Approval and Consent {#s2_8}
----------------------------

The study was approved from the Institutional Review Board of Imam Abdulrahman Bin Faisal University (IRB-UGS-2019-05-001). Permission was also obtained from the pharmacies. A written informed consent was obtained from patients before participation.

Results {#s3}
=======

A total of 318 patients consented to participate in the study. The reliabilities of GMAS and DKT questionnaires were reported at 0.81 and 0.75 respectively, i.e., satisfactory. The mean age of patients was 44 ± 15.5 years. The majority was male (N = 216, 67.9%), married (N = 231, 72.7%) with an income above SAR 10,000 (N = 150, 47.2%). Slightly less than half (N = 147, 46.2%) were university graduates. More than a third of patients had 1 -- 3 comorbidities (N = 147, 46.2%). More than a third of patients (N = 123, 38.7%) were prescribed at least two medicines. Most patients were on insulin therapy (N = 225, 70.8%). More than half of patients had government insurance (N = 189, 59.4%) ([**Table 1**](#T1){ref-type="table"}).

###### 

Demographic information (N = 318).

  Demographic information                                   Sample (N)   Percentage (%)
  --------------------------------------------------------- ------------ ----------------
  Gender                                                                 
   Male                                                     216          67.9
   Female                                                   102          32.1
  Marital status                                                         
   Married                                                  231          72.7
   Single                                                   87           27.3
  Monthly family income                                                  
   Less than SAR 5000 (i.e., \< USD 1332.7)                 54           17
   Between SAR 5000 to 7500 (i.e., USD 1332.7 to  1999.2)   36           11.3
   Between SAR 7500 to 10000 (i.e., USD 1999.2 to 2665.5)   78           24.5
   Above SAR 10000 (i.e., \> USD 2665.5)                    150          47.2
  Education level                                                        
   Primary education                                        60           18.9
   Secondary education                                      111          34.9
   Graduation                                               147          46.2
  Comorbidity                                                            
   No comorbidity                                           171          53.8
   Yes                                                      147          46.2
  Medicines per prescription                                             
   Single medicine                                          105          33
   Two medicines                                            123          38.7
   Up to three medicines                                    69           21.7
   Four or more medicines                                   21           6.6
  Prescribed insulin therapy                                             
   Yes                                                      225          70.8
   No                                                       93           29.2
  Health insurance                                                       
   Government insurance                                     189          59.4
   Company insurance                                        69           21.7
   Self-payment (No insurance)                              60           18.9

1 USD equals SAR 3.75.

Out of total 147 patients with comorbidities, 30.6% had one comorbidity (N = 45), 60.5% had 2 comorbidities (N = 89) and 8.9% had three comorbidities (N = 13). Those who had one comorbidity (N = 45, 30.6%) mainly had a disease of cardiovascular origin along with DM. Those who had two comorbidities (N = 89, 60.5%), had cardiovascular + other endocrine diseases for most part and, to some extent, cardiovascular + pulmonary diseases, cardiovascular + musculoskeletal diseases, and, cardiovascular + liver/kidney diseases. Those who had 3 comorbidities (N = 13, 8.9%), had a combination of either cardiovascular + other endocrine diseases + liver/kidney disease or, cardiovascular + other endocrine diseases + musculoskeletal diseases, etc.

The average adherence score was 25.3 out of total 33 \[median 27, IQR 7\]. A third of patients (N = 105, 33%) had high adherence followed by same number of patients who were partially adherent. The average score for DKT-2 was 56.46 ± 16.7 out of 100. Most patients (N = 162, 50.9%) had disease knowledge score between 51--75%. ([**Table 2**](#T2){ref-type="table"}).

###### 

Patients scores.

  Adherence and disease knowledge scores            Sample (N)   Percentage (%)
  ------------------------------------------------- ------------ ----------------
  GMAS adherence score                                           
   High adherence 30 -- 33                          105          33
   Good adherence 27 -- 29                          81           25.5
   Partial adherence 17 -- 26                       105          33
   Low adherence 11 -- 16                           21           6.6
   Poor adherence 0 -- 10                           6            1.9
  Diabetes Knowledge Test (DKT) score percentiles                
   Between 76--90% correct answers                  27           8.5
   Between 51--75% correct answers                  162          50.9
   Between 25--50% correct answers                  117          36.8
   Less than 25% correct answers                    12           3.8

Mean Hb~A1c~ value was 8.1%. There was a significant, negative, moderate-to-strong relationship between adherence score and, Hb~A1c~ values (ρ = --0.423, p \< 0.01). Similarly, there was a significant, negative and weak-to-moderate relationship between Hb~A1c~ values and disease knowledge (ρ = --0.199, p \< 0.01). Moreover, there was a significant, positive, weak-to-moderate correlation (ρ = 0.221, p \< 0.01) between adherence and disease knowledge scores of diabetic patients ([**Figures 1**](#f1){ref-type="fig"}--[**3**](#f3){ref-type="fig"}).
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There was a significant association between GMAS adherence percentiles and monthly family income (χ^2^ = 56.85, p \< 0.01). The patients with a monthly family income less than SAR 5000 were observed in higher numbers in partial, low and poor adherence percentiles as compared to patients with higher income. Similarly, a significant association existed between adherence and education level (χ^2^ = 46.02, p \< 0.01) as graduates were mostly observed to have a high adherence compared to patients who had primary or secondary education. Besides, a significant association was observed between adherence and mode of obtaining medicines (χ^2^ = 23.97, p \< 0.01) as patients who obtained their medications by out-of-pocket expenditure were mostly seen in lower adherence percentiles.

There was a significant association between adherence and comorbidity (χ^2^ = 19.6, p \< 0.01) as patients with comorbidity were mostly observed in high and good adherence percentiles. A significant association was reported between adherence and number of medicines per prescription (χ^2^ = 51.65, p \< 0.01) as most patients prescribed with 2 medicines were mostly in high adherence percentile. Statistical significance was not achieved for association between adherence percentiles and; gender as well as, use of insulin ([**Table 3**](#T3){ref-type="table"}).

###### 

Cross tabulation of dependent variables with GMAS score percentiles.

  Monthly family income                  GMAS adherence percentiles   P-value                                        
  -------------------------------------- ---------------------------- ----------- ----------- ----------- ---------- ----------
  Gender                                                                                                             \>0.05
   Male                                  72 (71.3)                    54 (55)     72 (71.3)   12 (14.3)   6 (4.1)    
   Female                                33 (33.7)                    27 (26)     33 (33.7)   9 (6.7)     0 (1.9)    
  Monthly family income                                                                                   \<0.01\*   
   \< SAR 5000                           6 (17.8)                     12 (13.8)   24 (17.8)   9 (3.6)     3 (1)      
   SAR 5000 - 7500                       18 (11.9)                    9 (9.2)     6 (11.9)    3 (2.4)     0 (7)      
   SAR 7500 - 10000                      15 (25.8)                    27 (19.9)   27 (25.8)   9 (5.2)     0 (1.5)    
   \> SAR 10000                          66(49.5)                     33 (38.2)   48 (49.5)   0 (9.9)     3 (2.8)    
  Education                                                                                                          \<0.01\*
   Primary education                     18 (19.8)                    27 (15.3)   12(19.8)    3 (4.0)     0 (1.1)    
   Secondary education                   27 (36.7)                    27 (28.3)   36 (36.7)   15 (7.3)    6 (2.1)    
   Graduation                            60 (48.5)                    27 (37.4)   57 (48.5)   3 (9.7)     0 (2.8)    
  How do you obtain diabetic medicines                                                        \<0.01\*               
   Government supply                     60 (62.4)                    45 (48.1)   75 (62.4)   9 (12.5)    0 (3.6)    
   Insurance                             30 (22.8)                    15 (17.6)   15 (22.8)   6 (4.6)     3 (1.3)    
   Out-of-pocket cost                    15 (19.8)                    21 (15.3)   15 (19.8)   6 (4)       3 (1.1)    
  Use of insulin                                                                                                     \>0.05
   Yes                                   69 (74.3)                    54 (57.3)   84 (74.3)   15 (14.9)   3 (4.2)    
   No                                    36 (30.7)                    27 (23.7)   21 (30.7)   6 (6.1)     3 (1.1)    
  Comorbidity                                                                                                        \<0.01
   Comorbidity present                   51 (53.5)                    54 (41.3)   42 (53.5)   9 (10.7)    6 (3.1)    
   No comorbidity                        54 (51.5)                    27 (39.7)   63 (51.5)   12 (10.3)   0 (2.9)    
  Medicines per prescription                                                                              \<0.01\*   
   1 medicine                            21 (34.7)                    24 (26.7)   48 (34.7)   9 (6.9)     3 (2.0)    
   2 medicines                           66 (40.6)                    24 (31.3)   24 (40.6)   6 (8.1)     3 (2.3)    
   3 medicines                           12 (22.8)                    27 (17.6)   24 (22.8)   6 (4.6)     0 (1.3)    
   4 or more medicines                   6 (6.9)                      6 (5.3)     9 (6.9)     0 (1.4)     0 (0.4)    

SAR = Saudi Arabian Riyal, 1 USD equals 3.75 SAR, \*Fisher Exact test.

Further analysis using multiple logistic regression revealed that patients who had a monthly family income above SAR 10,000 were five times more likely to be adherent (AOR = 5.4, p \< 0.01) compared to patients with income lower than SAR 5,000. Besides, patients with comorbidity were two to three times more likely to be adherent to their medications (AOR = 2.7, p \< 0.01). Moreover, patients who obtained their medications from insurance were four times more likely to be adherent as compared to those patients who paid out-of-pocket. On the negative side, patients with primary education were less likely to be adherent (AOR = 0.3, p \< 0.01) compared to patients who were graduates. Finally, patients who answered more than 50% correct answers in the diabetes knowledge test questionnaire were observed to be 4--5 times more likely to be adherent to their medications (AOR 4.46, p \< 0.01). The model was adjusted for age, income, education comorbidity and method of obtaining medicines, to amend for potential confounder of the relationship between disease knowledge and medication adherence. The model for medication adherence is tabulated in [**Table 4**](#T4){ref-type="table"}. In multiple logistic regression, "Enter" method was applied, multicollinearity was checked and was not found. Hosmer-Lemeshow test value was reported at χ2 = 11.334, p = 0.183 while Nagelkerke R Square value was 0.497.

###### 

Model for medication adherence.

  ------------------------------------------------------------------------------------------------------
  Variables                             B        S.E.    P value   Adjusted OR   95% CI of OR   
  ------------------------------------- -------- ------- --------- ------------- -------------- --------
  Age                                   0.031    0.012   0.007     1.032         1.009          1.056

  Monthly income                                         0.000                                  

   SAR Less than 5,000 (R)              --       --      --        --            --             --

   Between SAR 5,000 to 10,000          1.420    0.465   0.000     4.155         3.695          13.185

   SAR Above 10,000                     1.686    0.473   0.000     5.400         4.718          18.763

  Education level                                        0.000                                  

   Graduation (R)                       --       --      --        --            --             --

   Primary level                        -1.098   0.462   0.017     0.333         0.135          0.825

   Secondary level                      1.176    0.592   0.047     3.241         1.015          10.350

  Comorbidity                                                                                   

   No (R)                               --       --      --        --            --             --

   Yes                                  1.002    0.360   0.005     2.724         1.346          5.515

  Medicine obtain from                                   0.000                                  

   Out-of-pocket (R)                    --       --      --        --            --             --

   Government supply                    1.026    0.387   0.008     2.791         1.307          5.958

   Company insurance                    1.393    0.581   0.000     4.028         3.849          7.594

  Diseases knowledge                                                                            

   Less than 50% correct  answers (R)   --       --      --        --            --             --

   Between 50% to\                      1.496    0.320   0.000     4.465         2.385          8.362
   100% correct answers                                                                         
  ------------------------------------------------------------------------------------------------------

AOR, Adjusted odds ratio; CI, Confidence Interval.

Discussion {#s4}
==========

Several studies have been conducted on measuring adherence to medications as well as knowledge regarding disease in Saudi patients with diabetes however, studies that examine the link between adherence and disease knowledge are lacking. This study was novel in this aspect and reported a weak-to-moderate positive relationship between the two. Moreover, it further revealed a moderate-to-strong negative relationship between adherence score and glycated haemoglobin A1c value as well between disease knowledge and same. Hb~A1c~ was considered as a proxy for disease control as the American Diabetes Association (ADA) mentions a better Hb~A1c~ value as an indicator for adequate glycemic control over 4 months ([@B40]). This approach has been previously used by [@B11] in Saudi patients with T2DM. All correlations were statistically significant. This implied that patients who had better adherence and disease knowledge demonstrated better glycemic control. Moreover, it further highlighted that knowledge about the disease and adherence to therapy were related. Better knowledge contributes to better adherence. This finding was in line with previously reported literature that mentions disease literacy as a determinant of achieving positive treatment outcomes ([@B43]; [@B11]). Our findings are in line with the results of [@B35] as there was a negative relationship between Hb~A1c~ value and, adherence and disease knowledge in patients with diabetes in Pakistan. Moreover, we also found disease knowledge as a determinant of adherence as patients with more than average knowledge of diabetes were 4 to 5 times more likely to be adherent to medications. In another study, patients with Hb~A1c~ values less than 6.5% had better disease knowledge and adherence ([@B12]). In a systematic review, [@B26] reported that disease knowledge was a determinant of persistence. Better disease knowledge results in improved symptom recognition and self-management. It empowers patients to understand the importance of adherence and consequences of non-adherence ([@B45]). Based on health behavior theory, patients would choose a behavioral option that helps them achieve a healthy status which in this case would be adhering to prescribed therapy that improves glycemic control ([@B13]; [@B35]).

The scores for disease knowledge and adherence reported for Saudi patients were not satisfactory as less than 60% had high-to-good adherence and majority had average disease knowledge. This increases the likelihood of negative disease outcomes such as micro and macro vascular complications namely cardiovascular diseases, eyes and kidney damage, etc. Besides, it could also result in cerebrovascular events such as stroke. All these outcomes contribute to disability, morbidity, increase economic burden and lost productivity. These outcomes could worsen the health-related quality of life of diabetic patients and may increase likelihood of mortality in severe cases. Moreover, psychological impact of such outcomes may result in the form of depression. In this context, a study in Pakistan reported undiagnosed depression in diabetic patients ([@B2]). Hence, this knowledge barrier could be a reason that diabetes remains as one of the main causes of death and disability in Saudi Arabia ([@B23]).

Increasing health literacy remains a challenge in Saudi population. Recently, a large sample size study highlighted that more than half of Saudi population had low health literacy. The study stressed on the need to design and execute health literacy programs and campaigns ([@B4]). Quite the reverse, [@B27] reported that there was high health literacy that was not associated with glycemic control, in Saudi patients with type 2 diabetes. Our study results contradict the findings of [@B27]. This was evident in this study as most patients were graduates but had unsatisfactory disease awareness. An average Hb~A1c~ value of 8.1% explains that despite being educated, the patients' diabetes were not adequately controlled. Moreover, most patients were on insulin therapy which further strengthen this proposition. This finding was in line with the work of [@B36]. The study further highlighted that individual patient characteristics such as education, income, insurance and comorbidities may act as determinants of medication adherence. This occurrence was in line with previous study by [@B11]. However, the fact that education does not act as a determinant of disease awareness in this population uncovers the need to initiate diabetes awareness campaigns to educate patients about the disease, its symptoms and self-management that includes adherence to treatment. All healthcare professionals need to play a role in patient education.

Pharmacists fill prescriptions for patients after consultations. They are last healthcare professional patients see before leaving the hospitals. Pharmacist provide routine drug information service in Saudi hospitals ([@B7]). Therefore, educational interventions by pharmacist could be more beneficial as compared to interventions by other HCPs. Moreover, pharmacists provide pharmaceutical care in which one of the core areas is patient education ([@B39]; [@B32]). Studies that evaluate the benefits of an educational intervention by pharmacists to improve disease knowledge and adherence are recommended. The use of convenience sampling might have made it difficult to generalize the findings however, the demographics obtained in the current study were quite similar to the results of study by [@B11] that used random sampling. Nonetheless, the results should be interpreted with caution.

Conclusion {#s5}
==========

The disease knowledge in most patients was average and half of patients had high-to-good adherence. A significant weak-to-moderate correlation between disease knowledge and medication adherence was present. Moreover, there was a significantly moderate-to-strong, negative relationship between Hb~A1c~ and, disease knowledge as well as adherence. This revealed that glycemic control was better in patients with good knowledge of diabetes and high adherence to anti diabetic medications. A positive relationship between disease knowledge and adherence score was observed that highlights the impact of disease awareness on treatment concordance. This may result in better control of disease. These results highlight the importance of patient education and awareness regarding medication adherence in managing diabetes.
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